Skip to main content
Signal8
Launch Terminal

Radiopharm Theranostics Ltd (RADX)

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Radiopharm Theranostics Limited logo

Radiopharm Theranostics Limited

NASDAQ:RADXHealthcare
-3.26%$1.08
AH$1.08+0.00%vs close
Mkt Cap$16.96M
Float9.34M
O/S15.7M
Vol
$ Vol
RVOL
Inst Own-
SI1.5%
Earnings
Dilution
Radiopharm Theranostics Limited logoNASDAQ:RADX$1.08-3.26%
Phase Distribution
7 lead-sponsored trials·6 active·0 completed
Early Phase 12
Phase 12
Phase 1/22
Phase 21
Status Overview
Not yet recruiting1
Recruiting4
Active, not recruiting2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Active, not recruiting

    Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases

    RAD101 (18F-FPIA)

    Brain Metastases From Solid Tumors

    Enrollment
    30
    Start
    Dec 2024
    Primary Completion
    Apr 2026
    Completion
    Oct 2026est.
    NCT06777433
  • Phase 1/2
    Recruiting

    177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    177Lu-BetaBart, BetaBart + unlabeled BetaBart

    Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer +9

    Enrollment
    61
    Start
    Feb 2026
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT07189871
  • Phase 1/2
    Recruiting

    A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC

    161Tb RAD402

    Castration-resistant Prostate Cancer

    Enrollment
    73
    Start
    Mar 2026
    Primary Completion
    Nov 2028est.
    Completion
    Mar 2029est.
    NCT07259213
  • Phase 1
    Active, not recruiting

    Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

    RAD301 ([68Ga]-RAD301)

    Healthy Volunteers, Pancreatic Ductal Adenocarcinoma +5

    Enrollment
    9
    Start
    Nov 2023
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2026est.
    NCT05799274
  • Phase 1
    Not yet recruiting

    A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.

    LNTH-2403

    Imaging, Colorectal Cancer +3

    Enrollment
    16
    Start
    Oct 2026est.
    Primary Completion
    Aug 2027est.
    Completion
    Oct 2027est.
    NCT07272642
  • Early Phase 1
    Recruiting

    177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

    177Lu-RAD204

    PDL1 Gene Mutation, Non Small Cell Lung Cancer +7

    Enrollment
    30
    Start
    Jun 2024
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT06305962
  • Early Phase 1
    Recruiting

    HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

    177Lu-RAD202

    HER2 Gene Mutation, Advanced Solid Tumors

    Enrollment
    30
    Start
    Feb 2025
    Primary Completion
    Dec 2027est.
    Completion
    Dec 2027est.
    NCT06824155
Search ClinicalTrials.gov for “Radiopharm Theranostics”